Immunologic Approaches to Ovarian Cancer

描述（由申请人提供）：不到一年前，《科学》杂志将癌症免疫疗法评为“年度突破”。在这篇简短的社论中，Couzin-Frankel博士讨论了癌症免疫疗法的一些关键进展，包括ipilumumab（抗ctla -4）和nivolomab（抗PD-1）的发现和开发。通过包括Lloyd Old， James Allison和Jedd Wolchok在内的领导者，MSKCC一直是这两家代理商发展的一部分。Couzin-Frankel博士还提到了嵌合抗原受体（CAR） T细胞疗法的出现，并提到了MSKCC在2013年美国血液学学会上的抗白血病治疗报告，该报告由我们的研究员Renier Brentjens， Michel Sadelain等人领导。在下期的《科学》杂志上，另一篇文章回顾了“糖基化治疗利用的新兴原则”。David Spriggs， Sam Danishefsky和Jerry Ravetch已经在糖基化蛋白领域工作了好几年，为疫苗开发和抗体Fc功能研究做出了贡献。该项目将这些领域和研究人员聚集在一起，研究免疫疗法如何改变卵巢癌的治愈率和生存率。该项目的总体目标将是：增加宿主免疫系统与高级别浆液性卵巢癌之间相互作用的知识。我们希望将这些知识转化为卵巢癌妇女的改进治疗和更长的无症状生存期。项目包括4个项目：1)MUC16糖生物学；卵巢癌个体化疫苗治疗；改良t细胞治疗卵巢癌的研究进展和Fc修饰抗muc16外结构域抗体，提高疗效。

DESCRIPTION (provided by applicant): In less than a year ago, Science magazine identified Cancer Immunotherapy as the "Breakthrough of the Year". In this short editorial, Dr Couzin-Frankel discusses some of the key developments in Cancer Immunotherapeutics, including the discovery and development of ipilumumab (anti-CTLA-4), nivolomab (anti- PD-1). MSKCC has been a part of the development of both agents through leaders including Lloyd Old, James Allison, and Jedd Wolchok. Dr. Couzin-Frankel also mentions the advent of Chimeric Antigen Receptor (CAR) T cell therapy and refers to MSKCC's report of anti-leukemia therapy in 2013 American Society of Hematology, led by our investigators Renier Brentjens, Michel Sadelain and others. In the next issue of Science, another article reviewed "Emerging Principles for the Therapeutic Exploitation of Glycosylation". David Spriggs, Sam Danishefsky, and Jerry Ravetch have been part of the glycosylated protein field for several years, contributing to vaccine development and antibody Fc functional studies. The program brings these fields and investigators together to examine how immunotherapy can change the cure rates and survival in ovarian cancer. The overall Objective of the program will be: to increase the knowledge about the interactions between the host immune system and High Grade Serous Ovarian Cancer. We expect to translate that knowledge into improved treatments and longer symptom free survival for women with ovarian cancer. The program will include 4 projects: 1) MUC16 glycobiology; Personalized Vaccine Therapy in ovarian cancer; Modified T-cell Therapy of Ovarian Cancer; and Fc Modification of anti-MUC16 ectodomain antibodies to enhance efficacy.